White House Names Monica Bertagnolli as NCI Director

The announcement confirms earlier reports that Bertagnolli will become the first woman to lead the National Cancer Institute since its founding in 1937.

Written byAndy Carstens
| 2 min read
National Cancer Institute, Shady Grove Campus
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The White House announced today (August 10) that Harvard cancer surgeon Monica Bertagnolli will become the next director of the National Cancer Institute, which oversees the Cancer Moonshot Initiative and funds the majority of US cancer research. Bertagnolli will replace Ned Sharpless, who resigned the post in April, to become the first female director of the NCI since the agency was founded in 1937, STAT reported last month. The institute is the largest within the National Institutes of Health and has an annual budget of nearly $7 billion.

“Dr. Bertagnolli is a terrific choice to be the 16th director of the National Cancer Institute,” Sharpless tells STAT. “She’s a marvelous surgeon and national leader in cancer clinical trials. She’s just the right person to lead President Biden’s ‘Cancer Moonshot,’” an initiative to cure cancer created by Biden as Vice President in 2016, soon after his son had died of brain ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • A black and white headshot of Andrew Carstens

    Andy Carstens is a freelance science journalist who is a current contributor and past intern at The Scientist. He has a bachelor’s degree in chemical engineering from the Georgia Institute of Technology and a master’s in science writing from Johns Hopkins University. Andy’s work has previously appeared in AudubonSlateThem, and Aidsmap. View his full portfolio at www.andycarstens.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies